Velkommen til
Hvem er vi
Dansk Selskab for Klinisk Cannabismedicin (DSKCan) blev i 2022 stiftet som del af Lægevidenskabelige Selskaber under Lægeforeningen med det formål at afsøge mulighederne for anvendelse af cannabismedicin i patientbehandlingen og fremme evidensbaseret klinisk forskning inden for området.
I 2018 vedtog Folketingen en midlertidig forsøgsordning, hvor man lovliggjorde behandling med cannabismedicin i Danmark. For at sikre rammerne for et fælles møde forum for læger og øvrige sundhedsprofessionelle samt forskere, repræsentanter fra patientforeninger og andre personer med interesse for cannabismedicin tog Center for Klinisk Forskning ved Regionshospital Nordjylland derfor initiativ til dannelse af Klinisk Cannabis Forum, hvor man afholdt nogle møder og udarbejdede en klinisk behandlingsvejledning samt udgav et mini-kompendium for læger i anvendelsen af cannabismedicin.
Efter fire års virke i forbindelse med udløbet af første periode af forsøgsordningen blev Klinisk Cannabis Forums mission vurderet som værende afsluttet og i forlængelse heraf blev DSKCan etableret som et fælles forum med større fokus på inddragelse af læger og forskere samt andre personer med sundhedsfaglig interesse indenfor cannabismedicin.
Objective Agitation and related neuropsychiatric symptoms are common in Alzheimer’s disease (AD) and contribute to caregiver burden, functional decline, and institutionalization. Cannabinoid-based therapies have been investigated as potential symptomatic interventions, but evidence remains limited by small trials, heterogeneous formulations, and variable outcome reporting. We aimed to evaluate the efficacy, cognitive outcomes, and safety of cannabinoid-based […]
Fibromyalgia is a chronic disorder characterised by widespread pain and other symptoms that substantially impact the quality of life. This double-blind, randomised, placebo-controlled trial primarily assessed feasibility (procedures and intervention adherence) and safety/tolerability of a 1:1 delta-9-tetrahydrocannabinol:cannabidiol (THC:CBD) cannabis oil (10 mg/mL each) in 24 adults with fibromyalgia, with secondary, preliminary assessment of efficacy across symptom […]
Cannabis use, both medical and recreational, is increasing and poses a growing challenge for anesthesiologists, given the scarcity of specific clinical data. The main phytocannabinoids, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), interact with CB1 and CB2 receptors, affecting cardiovascular, respiratory, neurological, and immune systems, as well as the metabolism of several anesthetic drugs. Chronic or high-dose […]
Therapeutic effects of cannabinoids on Parkinson’s disease: an updated systematic review and meta-analysis of randomized controlled trials Purpose: Current treatments for Parkinson’s disease (PD) are primarily symptomatic and may lead to motor fluctuations and levodopa-induced dyskinesia over time, highlighting the need to repurpose other medications. Cannabinoids have gained attention as potential repurposed treatments. This systematic review […]